1. Lifecore signed a CDMO agreement with a large pharmaceutical customer. 2. The agreement includes tech transfer for injectable pharmaceutical products. 3. This new partner may become one of Lifecore's top five clients. 4. Lifecore's recent agreements highlight its competitive advantages in quality and expertise. 5. The agreement signifies regulatory confidence and future growth potential.
FAQ
Why Bullish?
The new contract with a large customer indicates increasing demand for Lifecore's services, similar to past occasions where new partnerships led to stock price increases during growth phases.
How important is it?
The partnership increases revenue streams and market position, crucial for LFCR's growth, indicating a strong likelihood of a positive impact on the stock price.
Why Long Term?
The impact of becoming a top customer and gaining new business usually unfolds over several quarters, as regulatory approvals and customer transitions take time.
Lifecore Biomedical Secures CDMO Agreement with New Global Pharmaceutical Partner
CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR), a leading contract development and manufacturing organization (CDMO), has announced the signing of a significant master services agreement with a prominent multinational pharmaceutical company. The agreement is set to facilitate development services and technical transfer for an injectable pharmaceutical product, paving the way for Lifecore to assume commercial manufacturing responsibilities.
Key Details of the Agreement
Under the terms of this new arrangement, Lifecore will focus on transferring commercial supply from existing overseas facilities to its state-of-the-art production sites. Successful completion of technical transfer activities and adherence to regulatory requirements will position Lifecore as the primary commercial supplier for this product.
- This is Lifecore's second agreement in three months with a multinational pharmaceutical entity.
- The new partner is projected to rank among Lifecore's top five commercial customers, driven by anticipated revenues from this project.
Leadership Insights on the Agreement's Impact
Paul Josephs, CEO of Lifecore, expressed enthusiasm about the company’s accelerating momentum as 2025 concludes. He stated, “Attracting and winning new business from two prominent pharmaceutical companies in quick succession speaks to our team’s ability to communicate our competitive differentiation in quality, technical expertise, and reliability for sterile injectables.” Josephs emphasized his gratitude for the trust placed in Lifecore and the company’s commitment to enhancing healthcare outcomes.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (NASDAQ: LFCR) is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations. With over 40 years of experience, Lifecore is recognized as a premier manufacturer of injectable-grade hyaluronic acid, serving global and emerging biotech firms across various therapeutic areas. For further information, visit www.lifecore.com.
Forward-Looking Statements
This announcement includes forward-looking statements that are subject to various risks and uncertainties. Such statements may involve expectations regarding future operational and financial results, including anticipated revenues and the progression of Lifecore's CDMO business. The company stresses that actual outcomes may differ materially from those forecasts due to numerous factors including market conditions, regulatory compliance challenges, and other economic variables.